Diabetes and Bone Fragility: SGLT2 Inhibitor Use in the Context of Renal and Cardiovascular Benefits
Kristen M. Jackson, Kendall F. Moseley
Topics & Concepts
CanagliflozinMedicineEmpagliflozinDapagliflozinBone remodelingInternal medicineBone mineralBone fractureDiabetes mellitusEndocrinologyType 2 Diabetes MellitusContext (archaeology)Intensive care medicineOsteoporosisPaleontologyRadiologyBiologyParathyroid Disorders and TreatmentsDiabetes Treatment and ManagementBone health and osteoporosis research